Sona Nanotech Inc

Canadian Securities Exchange:SONACanadaView on OTCQB

Sona Nanotech Inc. is a nanotechnology life sciences company, which is engaged in developing targeted hyperthermia therapy. The Company has developed multiple methods for the manufacturing of various types of gold nanoparticles (GNR). It is engaged in research and development of its technology for use in multiplex diagnostic testing platforms and advanced biomedical applications. Its gold nanotechnologies are adapted for use in applications, as a safe and delivery system for multiple medical treatments, for the approval of various regulatory boards, including Health Canada and the Food and Drug administration (FDA). Its gold nanorod particles are manufactured without the use of cetyltrimethylammonium bromide (CTAB), eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. The Company is focused on the development of a pre-clinical nanomedical therapy for the treatment of cancer using its biocompatible GNR.

Contact Information

Headquarters

Purdy's Wharf Tower 2 1969 Upper Water St Suite 2001HALIFAX, NS, Canada B3J 3R7

Phone

902-442-0653

Fax

902-482-1240

Executives

President, Chief Scientific Officer

Darren Rowles

Chief Executive Officer

David Regan

Chief Financial Officer, Corporate Secretary

Robert Randall

Director

Harold Megann

Director

Wayne Myles